CEGX Back to portfolio

The TrueMethyl® Seq kit


DNA/protein in bar-coded sample tubes.


Nuclear transfer, pipette inserted into egg


May 2012
Syncona meets with founders to review commercial opportunities for new method of sequencing novel base modification 5 hydroxymethylcytosine
August 2012
Syncona commits £500k in seed financing of the company
May 2016
Cambridge Epigenetix announces a $21m Series B investment by Google Ventures, Sequoia, New Science Ventures and Syncona

Company Details


Research tools

Fully diluted ownership


Value of Syncona holding



CEGX is developing research tools which provide detailed resolution of epigenetic changes to DNA, a key piece of information which has clear research utility and clinical potential as a diagnostic tool for diseases such as cancer.

CEGX was Syncona’s first investment, made in 2012, and was formed out of the work of Professor Sir Shankar Balasubramanian, the co-inventor of the market leading sequencing platform now commercialised by Illumina Inc.


Jason Mellad

Syncona Representatives
  • Martin Murphy
Head of R&D
  • Toby Ost